BiotechTube

Placebo + KRN23

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

X-linked Hypophosphatemia

Conditions

X-linked Hypophosphatemia

Trial Timeline

Dec 1, 2008 → May 1, 2013

NCT ID
NCT00830674

About Placebo + KRN23

Placebo + KRN23 is a phase 1 stage product being developed by Kyowa Kirin for X-linked Hypophosphatemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00830674. Target conditions include X-linked Hypophosphatemia.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT00830674Phase 1Completed

Competing Products

20 competing products in X-linked Hypophosphatemia

See all competitors
ProductCompanyStageHype Score
VK0214Viking TherapeuticsPhase 1
28
Methylprednisolone + Prednisolone + SirolimusAstellas PharmaPhase 1/2
41
BurosumabKyowa KirinPhase 1/2
41
BurosumabKyowa KirinPre-clinical
23
BurosumabKyowa KirinPre-clinical
23
BurosumabKyowa KirinPhase 2
52
KRN23Kyowa KirinPhase 1/2
41
KRN23Kyowa KirinPhase 3
77
burosumab + Oral Phosphate Supplement + active vitamin DKyowa KirinPhase 3
77
burosumabKyowa KirinPhase 3
77
KRN23Kyowa KirinApproved
85
burosumabKyowa KirinPhase 2
52
BurosumabKyowa KirinPhase 3
77
KRN23Kyowa KirinPhase 1/2
41
BurosumabKyowa KirinPhase 3
77
burosumabKyowa KirinPhase 3
77
KRN23Kyowa KirinPhase 2
52
KRN23Kyowa KirinPhase 1
33
KRN23Kyowa KirinApproved
85
KK8123Kyowa KirinPhase 1/2
41

Other Products from Kyowa Kirin

KRN23Approved
85
Istradefylline PillApproved
85
MogamulizumabApproved
85
KRN23Approved
85
KHK4827-Active + KHK4827-PlaceboApproved
85